RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2728
https://www.valueinhealthjournal.com/article/S1098-3015(23)02918-2/fulltext
Title :
RWD178 Real-World Treatment Patterns, Healthcare Resource Utilization (HRU) and Costs for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): Chimeric Antigen Receptor T-Cell (CAR T) and Monoclonal Antibodies (MAB) Therapies
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02918-2&doi=10.1016/j.jval.2023.03.2728
First page :
Section Title :
Open access? :
No
Section Order :
11528